Rivus Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Rivus Pharmaceuticals operates as a biopharmaceutical company dedicated to improving cardio-metabolic health. Rivus Pharmaceuticals is dedicated to improving cardio-metabolic health by developing controlled metabolic accelerators (CMAs) that address the underlying metabolic risk factors for cardiovascular mortality and morbidity.
Rivus Pharmaceuticals has raised $132M across 1 funding round on record, the most recent a Series B of $132M announced in Sep 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Rivus Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Sep 2022.
Rivus Pharmaceuticals Funding Rounds
Rivus Pharmaceuticals Founders and Leadership Team
Contact details for the Rivus Pharmaceuticals team: 1 of 1 has an email address on file.
Start 14-day free trial →Rivus Pharmaceuticals Funding Compared to Other Biotechnology Startups
Rivus Pharmaceuticals' latest round of $132M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Rivus Pharmaceuticals in Biotechnology and Charlottesville
Companies Similar to Rivus Pharmaceuticals
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Rivus Pharmaceuticals Funding FAQs
What does Rivus Pharmaceuticals do?
Rivus Pharmaceuticals operates as a biopharmaceutical company dedicated to improving cardio-metabolic health. Rivus Pharmaceuticals is dedicated to improving cardio-metabolic health by developing controlled metabolic accelerators (CMAs) that address the underlying metabolic risk factors for cardiovascular mortality and morbidity.
How much funding has Rivus Pharmaceuticals raised?
Rivus Pharmaceuticals has raised $132M across 1 round on record. The most recent is a Series B of $132M announced in Sep 2022.
When did Rivus Pharmaceuticals last raise funding?
Rivus Pharmaceuticals' most recent funding round on record is a Series B of $132M, announced in Sep 2022.
Who is the CEO of Rivus Pharmaceuticals?
Allen Cunningham is listed as CEO at Rivus Pharmaceuticals.
Where is Rivus Pharmaceuticals headquartered?
Rivus Pharmaceuticals is based in Charlottesville, Virginia, United States.
How many employees does Rivus Pharmaceuticals have?
Rivus Pharmaceuticals is in the 11-50 employee band.
How does Rivus Pharmaceuticals' funding compare to other Biotechnology startups?
Rivus Pharmaceuticals' latest round of $132M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Rivus Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Rivus Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.